• Genetic TherapyEnrolling

  Study of ARCT-032 in adults with cystic fibrosis who are not on CFTR modulator therapy. , protocol number Arcturus ARCT-032-02 Cohort 4

  This study will test the safety, tolerability and effectiveness of ARCT-032, a nebulized therapy intended to deliver a new, correct copy of CFTR messenger RNA (mRNA) to cells.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    45 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    24 weeks

• Anti-InfectiveEnrolling

  Study to evaluate AZD0292 in people 12 years of age and older with bronchiectasis and chronic Pseudomonas aeruginosa, including people with and without CF. , protocol number AstraZeneca AZD0292 CLEAR Phase 2b

  This study will evaluate the safety and effectiveness of AZD0292, a drug intended to prevent exacerbations in people with bronchiectasis and chronic Pseudomonas.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25% or greater

  • Number of Visits:

    21

  • Length of Participation:

    12 months

• Nutritional-GIEnrolling

  Study to evaluate ANG003 in people with CF ages 12 and older , protocol number Anagram ANG003-25-201

  This study will assess the safety and effectiveness of ANG003, a pancreatic enzyme replacement therapy, also known as “enzymes” or “enzyme therapy”, to see whether it works as well as the approved enzyme therapy Creon.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    6

  • Length of Participation:

    3 months

• ObservationalEnrolling

  Observational Study to Evaluate Anxiety, Depression, and Behavior Problems in Children With CF (TIDES 2.0) , protocol number TIDES 2.0 (SMITH24A0)

  The researchers conducting this observational study hope to learn more about the prevalence of mental health concerns in children with CF under age 12.

  • Age:

    18 Months to 11 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    3

  • Length of Participation:

    18 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.